MedTrace Logo

18F-Fluorocholine for the Detection of Parathyroid Adenomas

NCT03764007 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2021-10-19

Study results available
· View outcomes & findings →

Summary

The investigators are studying the ability of F18 labeled fluorocholine PET to localize parathyroid adenomas in patients with hyperparathyroidism prior to surgery.

Conditions

  • Hyperparathyroidism, Primary

Interventions

DRUG

18F-Fluorocholine

Given intravenously

PROCEDURE

Positron Emission Tomography (PET)

Imaging technique that uses radioactive agents known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities

Sponsors & Collaborators

  • Thomas Hope

    lead OTHER

Principal Investigators

  • Thomas Hope, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-21
Primary Completion
2021-05-31
Completion
2021-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03764007 on ClinicalTrials.gov